Prior to its acquisition, Nuvalent successfully secured significant venture capital and institutional backing through multiple strategic financing rounds, raising a total of approximately 185 million dollars. Its funding milestones included a 50 million dollar Series A financing round led by Deerfield Management, followed by a substantial 135 million dollar Series B financing round supported by prominent life science investors including Bain Capital Life Sciences and Fidelity Investments.